Re­volv­ing door be­tween in­dus­try and FDA con­tin­ues to spin

7 years ago
People
Pharma

Cir­cled by ri­val phar­ma gi­ants and a biotech pow­er­house, Ko­di­ak asks for a $100M-plus IPO for new eye drug

7 years ago
Financing

The pain won't stop. GSK ends the week with a slap­down on its Nu­cala ap­pli­ca­tion for COPD

7 years ago
Pharma

Ele­vian banks $5.5 mil­lion seed round to pur­sue 'y­oung blood' de­rived an­ti-ag­ing tech

7 years ago
Discovery

Ovid ex­ec Yaron Wer­ber cross­es back to Cowen; Saqib Is­lam pro­mot­ed to Spring­Work­s' first CEO slot

7 years ago
Peer Review

GSK’s flop Poti­ga is picked up and head­ed for a quick makeover for pe­di­atric epilep­sy. Any bets on the prospec­tive ...

7 years ago
Pharma

MPM, No­var­tis lead a big launch round for Kazu­mi Sh­iosa­ki’s lat­est biotech start­up com­ing out of Har­vard

7 years ago
Financing
Startups

As­traZeneca, Am­gen roll up a 'break­through' at the FDA in hot pur­suit of a po­ten­tial game chang­er in asth­ma

7 years ago
Pharma

Ham­mered hard by a sur­pris­ing FDA re­jec­tion, Io­n­is spin­out Akcea of­fers an ex­pla­na­tion and then chops 1-in-10 ...

7 years ago
R&D
Pharma

New in­vestors pool $120M to bankroll Al­lo­gene's off-the-shelf CAR-T pipeline in dri­ve to stay in the lead

7 years ago
Financing

Zealand hands off dis­ap­point­ing di­a­betes rev­enue from Sanofi in ex­change for a $205M in­jec­tion to back a new pipeline

7 years ago
R&D

Third Rock woos top Roche sci­en­tist San­jay Keswani to the helm of biotech start­up Rheos Med­i­cines

7 years ago
People
Startups

Atara brings an­oth­er ex­pe­ri­enced in­ves­ti­ga­tor on­to its off-the-shelf CAR-T quest in lat­est col­lab­o­ra­tion

7 years ago
R&D
Discovery

Ar­row­head touts hep B da­ta, shares rock­et up; Eli Lil­ly's an­i­mal health unit files big IPO

7 years ago
News Briefing

GSK chops 650 jobs, vow­ing to shift more mon­ey to a weak R&D ef­fort

7 years ago
Pharma

In a rare de­lay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecen­triq/Avastin triple for lung can­cer

7 years ago
Pharma

Juno will pay $24M to set­tle the JCAR015 scan­dal — but don’t ex­pect that to change in­dus­try at­ti­tudes on ...

7 years ago
Bioregnum
Opinion

Gilead, Gala­pa­gos clear an­oth­er PhII hur­dle for fil­go­tinib, but can they hope to catch up with No­var­tis’ Cosen­tyx?

7 years ago
R&D

A new CAR-T is cred­it­ed with a 'sur­pris­ing' im­pact in tiny study of ad­vanced liv­er can­cer — rais­ing hopes on sol­id ...

7 years ago
R&D

Li­cens­ing As­traZeneca castoff, Bio­haven preps PhI­II ef­fort in new neu­rode­gen­er­a­tive in­di­ca­tion

7 years ago
R&D
Pharma

What's up at Im­muno­core?; Pfiz­er nabs a key 'break­through'; Adap­ti­m­mune rais­es $100M

7 years ago
News Briefing

FDA waves Loxo through for sec­ond 'break­through' in tis­sue-ag­nos­tic can­cer ther­a­py

7 years ago
Pharma

Sang­amo team rush­es to de­fend first hu­man gene edit­ing da­ta as MPS II ther­a­py of­fers a hit — and a miss

7 years ago
R&D

Chi-Med, Eli Lil­ly score a land­mark ap­proval in Chi­na for the first new can­cer drug de­vel­oped in Chi­na

7 years ago
China
Pharma
First page Previous page 1012101310141015101610171018 Next page Last page
A service from the Financial Times